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Abstract 
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive, incurable cancer with a 20% one-year 
survival rate. While standard-of-care therapy can prolong life in a small fraction of cases, PDAC 
is inherently resistant to current treatments and novel therapies are urgently required. Histone 
deacetylase (HDAC) inhibitors are effective in killing pancreatic cancer cells in in vitro PDAC 
studies, and although there are a few clinical studies investigating combination therapy including 
HDAC inhibitors, no HDAC drug or combination therapy with an HDAC drug has been approved 
for the treatment of PDAC.  We developed an inhibitor of HDACs, AES-135, that exhibits 
nanomolar inhibitory activity against HDAC3, HDAC6, and HDAC11 in biochemical assays. In a 
3D co-culture model, AES-135 kills low passage patient-derived tumor spheroids selectively over 
surrounding cancer-associated fibroblasts (CAFs), and has excellent pharmacokinetic properties 
in vivo. In an orthotopic murine model of pancreatic cancer, AES-135 prolongs survival 
significantly, therefore representing a candidate for further preclinical testing. 
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Introduction 
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers, with only a 
20% one-year survival rate and a 7% five-year survival rate for all stages combined, and is widely 
considered incurable.1-2 It is currently the third leading cause of cancer-related mortality in the 
United States,3 and is characterized by a complex tumor microenvironment (TME) that is 
immunosuppressive and contains myeloid-derived suppressor cells (MDSCs) as well as cancer-
associated fibroblasts (CAFs), heterogeneity within the tumor, and an innate capacity for 
metastasis.4-7 Therefore, there is an imminent need for therapies in PDAC, inhibiting novel targets.  
Histone/lysine deacetylases (HDACs/KDACs) control post-translational protein 
acetylation,8-13 in conjunction with histone acetyltransferases (HATs), which fulfil an antagonistic 
role,9, 14 for a large number of substrates; most notably histones. By regulating histone 
acetylation/deacetylation, HATs and HDACs play a key indirect role in gene expression.11 
Oncogenic HDAC activity has been observed in aggressive human cancers, including pancreatic 
cancer.1-2, 15 To date, four small-molecule HDAC inhibitors have been approved by the FDA for 
hematological cancer treatment (Cutaneous T-Cell Lymphoma (CTCL), Peripheral T-Cell 
Lymphoma (PTCL) and Multiple Myeloma (MM)):8, 11, 13 SAHA (Vorinostat),16 Romidepsin 
(depsipeptide-FK228),17 Belinostat (PXD101),18 and Panobinostat (LBH-589).19 Current HDAC 
clinical trials in PDAC consist of adjuvant therapies using Vorinostat or Panobinostat in 
combination with radiation, surgery or standard-of-care chemotherapy.20-27 Three of the four 
HDAC drugs contain an N-hydroxamic acid, which mimics the hydrogen bonds formed by 
acetylated lysine substrates; competitively coordinating to the metal ion within the catalytic 
domain, rendering the HDAC inactive.8 The catalytic domain is the most structurally conserved 
region in the HDAC family primary sequence, and targeting of this domain by small molecules 
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often results in the inhibition of more than one HDAC. Despite this, clinical efficacy with pan-
HDAC inhibitors has been observed in select cancer sub-types, but with adverse side effects 
including diarrhea and bone marrow toxicity, observed in patients.8 HDAC inhibitors, with the 
exception of Romidepsin,28-30 possess a similar linear structural design; with a metal chelating 
group (e.g. hydroxamic acid) at one end and a hydrophobic capping group (e.g. a 2-methylindole) 
at the other, connected by a linear hydrophobic scaffold, e.g. a benzene ring or an alkyl chain.13, 31 
A lack of structural diversity might infer that many of the current clinical candidates are likely to 
encounter the same pitfalls in clinical trials.32 
 Herein, we introduce a small family of novel HDAC inhibitors, including lead compound, 
AES-135, which biochemically inhibits HDACs 3, 6, 8 and 11 with IC50 values of 190 – 1100 nM, 
and exhibits selective in vitro cytotoxicity in low passage patient-derived pancreatic cancer cells 
even in the presence of cancer-associated fibroblast (CAF) cells. AES-135 has other favourable in 
vivo properties such as metabolic stability in mouse hepatocytes and bioavailability in µM 
concentrations in NSG mice for >10 h (IP injection). AES-135 combines the proven attributes of 
an N-hydroxamic acid with a new chemotype for exploration as an HDAC inhibitor.  
 
Results and Discussion 
AES-135 was identified as part of a structure-activity relationship (SAR) study designed 
to repurpose a class of Signal Transducer and Activator of Transcription 3 (STAT3)-targeting 
compounds, including SH-4-54 (1, Table 1), toward HDACs.33-35 Efforts were predominantly 
focused on replacing the STAT3 SH2 domain-targeting benzoic acid substituent with an isosteric 
N-hydroxamic acid for HDAC catalytic domain targeting.36 A brief SAR around the general 
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structure of 1 sought to identify direct-binding nM IC50 HDAC inhibitors. A series of analogs were 
prepared with substitutions made at positions R1, R2 and R3 (Table 1).  
 
Table 1. IC50 Values for AES-135 and its Analogs Against HDACs 3, 6, 8 and 11, Evaluated up 
to 1 µM (EMSA, n=1) 
 
Substituents IC50 (µM) 
Compound # R1 R2 R3 HDAC3 HDAC6 HDAC8 HDAC11 
AES-135 t-Bu 4-F 2,3,4,5,6-F 0.654 0.190 >1 0.636 
2 t-Bu 3,4-F 2-CF3 >1 0.362 >1 0.254 
3 CF3 3,4-F 2-CF3 >1 0.188 >1 0.396 
4 t-Bu 2,4-F 2-CF3 >1 0.289 >1 0.288 
5 CF3 2,4-F 2-CF3 >1 0.151 >1 0.346 
6 t-Bu 4-F 2-CF3 >1 0.230 >1 0.253 
7 CF3 4-F 2-CF3 >1 0.093 >1 0.304 
8 CF3 4-F 2,3,4,5,6-F >1 0.086 >1 0.191 
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Compounds were synthesized as outlined in Scheme 1. Briefly, anilines 11 – 12 were prepared in 
good to excellent yields via reductive amination of benzyl 4-aminobenzoate 10 with different 
benzaldehydes under standard conditions. Glycine tert-butyl (t-Bu) ester hydrochloride (13) was 
sulfonylated, and the resulting sulfonamides 14 – 17 were benzylated under basic conditions. 
Removal of the t-Bu protecting group with diluted trifluoroacetic acid (TFA) furnished the 
carboxylic acids 23 – 27 quantitatively. Anilines and carboxylic acids were coupled using 
dichlorotriphenylphosphorane (PPh3Cl2) under microwave conditions, and subsequent 
hydrogenation cleaved the carboxybenzyl group. Chlorination of the benzoic acids using oxalyl 
chloride, followed by coupling with O-benzylhydroxylamine, generated the hydroxamate esters, 
and the O-benzyl group was removed by hydrogenation.  
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Scheme 1: Synthesis of N-hydroxamic acid-based HDAC inhibitors 
 
(a) BnBr, Cs2CO3, DMF, 24 h, RT; (b) (i) ArCHO, MgSO4, THF, 16 h, RT; (ii) NaBH4, TFE, 16 h, RT; (c) ArSO2Cl, 
iPr2NEt, CH2Cl2, 16 h, 0 °C-RT, N2; (d) BrCH2Ar, Cs2CO3, MeCN, 16 h, 50 °C-RT; (e) CF3CO2H/CHCl3 (1:3), 3 h, 
RT; (f) 11 or 12, PPh3Cl2, CHCl3, 1 h, 100 °C, N2, microwave; (g) H2, 10% Pd/C, THF/MeOH (2:1), 16 h, RT; (h) (i) 
(COCl)2, THF, DMF, 2 h, 0 °C, N2; (ii) H2NOBn, iPr2NEt, THF, 16 h, RT, N2. 
 
The R2 position of 1, occupied by a pentafluorobenzenesulfonamide, was substituted with less 
electron-deficient mono- and di-fluorinated benzene rings to minimize potential nucleophilic 
addition in vivo.35 The cyclohexyl R1 group reduced solubility and was susceptible to Phase I 
oxidation,35 so this was replaced with less lipophilic t-Bu and trifluoromethyl (CF3) groups.33 
Finally, the R3 N-methyl group, previously shown to be sensitive to oxidation in mouse 
hepatocytes, was substituted with either a pentafluorobenzyl or 2-(trifluoromethyl)benzyl 
appendage.37 The prepared library was evaluated for inhibitory activity against select HDACs 
representative of groups I (3 and 8), II (6) and IV (11) using an electrophoretic mobility shift assay 
(EMSA). In this assay, enzymatic deacetylation of a FAM-labelled peptide substrate is measured 
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as a change in the relative fluorescence intensity of the substrate and product following incubation. 
In the presence of an inhibitor, deacetylation is impeded, altering the fluorescence intensity of the 
product and substrate (a detailed procedure is provided in the supporting information). With the 
exception of AES-135, compounds in this library demonstrated selective activity for HDAC 
groups II and IV, with limited activity observed against either HDAC3 or HDAC8 (group I). AES-
135 exhibited nanomolar (nM) inhibition of HDACs 3, 6 and 11, with low-µM activity against 
HDAC8 (IC50 later confirmed to be 1.10 µM when AES-135 was evaluated up 10 µM against these 
targets (Supporting Information, Figure S22 – S25)). 
 
To explain the observed results, compounds were modelled in silico using AutoDock 
Vina/AutoDockTools v4.2.6. Specifically, AES-135 and 6 were chosen as representative ligands 
due to their differing HDAC selectivity profiles despite being structurally similar, differing only 
at the R3 position (pentafluorobenzyl vs. 2-(trifluoromethyl)benzyl, respectively). These 
compounds were docked against eukaryotic, zinc-dependent hHDAC 3, 6, and 8 (PDB: 4A69, 
5EDU, and 1T64) (Figure 1). hHDAC11 analysis was not possible, as no crystal structure has 
been resolved to date. A detailed description of the experiments performed can be found in the 
supporting information.  
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Figure 1. Computational modelling/docking studies of AES-135 against hHDAC 3, 6, and 8 
(PDB: 4A69, 5EDU and 1T64, respectively). (Left column) catalytic active site of enzyme, 
Zn2+ (yellow sphere), residues within/around lysine-substrate channel (shown as white ball-and-
stick), catalytic triad residues (shown as colored ball-and-stick). (Centre column) molecular 
surface view of channel entrance, low hydrophobicity residues (white), high hydrophobicity 
residues (red). (Right column) side view of ligands docked within the active site. Panel 
A: hHDAC6 (blue cartoon), AES-135 (magenta), SAHA (green). Panel B: hHDAC3 (green 
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cartoon), AES-135 (magenta), 6 (cyan). Panel C: hHDAC8 (red cartoon), AES-
135 (magenta), 6 (cyan). 
 
All three enzymes have a largely hydrophobic surface proximal to the lysine-substrate channel. In 
hHDAC6, the lysine tunnel surroundings are largely featureless and flat, while hHDAC3 and 8 
contain greater surface topology. While the importance of the metal binding group for HDAC 
targeting is critical, the contribution of the capping group to binding and selectivity among the 
HDAC isoforms is significant. Increased hydrophobic interaction between the enzyme surface and 
the capping group is postulated to greatly increase binding affinity.38-40 These interactions were of 
interest when analyzing the in silico binding conformations of AES-135 and 6 to hHDACs 3, 6 
and 8 (Figure 1), relative to the in vitro EMSA data shown in Table 1.  The docking of AES-135 
to hHDAC3, 6 and 8 returned average free energy of binding values (DGB) of -8.31 ± 0.08, -8.98 
± 0.17, and -8.80 ± 0.13 kcal/mol, while 6 scored -7.31 ± 0.44, -8.64 ± 0.17, and -7.74 ± 0.12 
kcal/mol, respectively (Supporting Information, Table S17 – S23). In silico, AES-135 binds more 
favorably to all three isoforms than 6, while having greater affinity for hHDAC3/8, yet has more 
comparable binding to hHDAC6. Comparing binding to hHDAC 3 and 8 (Figure 1, Panel B and 
C), the perfluorinated ring of AES-135 makes significantly more interactions with residues 
proximal to the channel, with minimal steric clash compared to the 2-(trifluoromethyl) group of 6, 
which appears to occupy poses that unfavourably clash with the HDAC surface.  
To confirm AES-135 as the lead candidate, cytotoxicity profiles were determined against a bank 
of human cancer cell lines (Supporting Information, Table S1 – S2, Figure S1 – S6). 
Encouragingly, AES-135 was shown to be the most promising candidate, with low µM potency 
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being observed in multiple brain tumor stem cell glioblastoma lines, MV4-11 and MOLM-13 
AML cells, and PC-3 prostate cancer cells. In D425 primary medulloblastoma (MDB) and D458 
recurrent MDB cells, nM activity was observed. Patient-derived pancreatic cancer cells were 
sensitive to single-digit µM/high nM concentrations of AES-135. Of the lines tested, only chronic 
myelogenous leukemia K562 cells were resistant to AES-135. Encouragingly, in MRC9 lung cells 
(non-cancerous), AES-135 demonstrated minimal toxicity, identifying a clear therapeutic window.  
To assess the stability of the pentafluorobenzyl (PFB) ring to biological nucleophiles, a 10 mM 
solution of AES-135 in DMSO was mixed with a 100-fold excess of reduced L-glutathione in 
HEPES buffer, pH 7.4, and monitored by analytical HPLC at regular intervals. No discernible 
reaction was observed, even after 25 h (Supporting Information, Figure S7 – S8). This was 
corroborated by 19F NMR studies, in which no displacement of fluoride was observed after 16 h 
of immersion in 100-fold excess glutathione (Supporting Information, Figure S9). 
Given the structural origin of AES-135 from 1, we confirmed that the cytotoxicity observed with 
the former was not due to STAT3/5 inhibition. Western blot studies were performed in MDA-MB-
231 breast cancer cells (STAT3-overexpressing) and MV4-11 AML cells (STAT5-
overexpressing). The results showed that AES-135 did not inhibit activation of STAT3 or STAT5 
signaling via immunoblotting for Y694 phosphorylation on STAT5b and Y705 phosphorylation 
on STAT3 (Supporting Information, Figure S10). In MDA-MB-231 cells, AES-135 returned an 
IC50 of 2.72 ± 0.60 µM (n = 4), yet even at 10-fold this concentration, neither total STAT3 nor 
pY705 STAT3 was significantly reduced. Similar results were observed in MV4-11 cells, where 
AES-135 had an IC50 of 1.88 ± 0.89 µM (n = 4), yet failed to suppress total STAT5b or pY694 
STAT5b, even at 10 µM. Evidence from Western blots in pancreatic Pa03C cancer cells and 
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multiple BTSC GBM lines was subsequently obtained, further supporting the conclusion that 
AES-135 was not a STAT3/5 inhibitor (Supporting Information, Figure S11 – S14). 
 To confirm that the N-hydroxamic acid group in AES-135 was responsible for HDAC targeting, 
the compound was screened against seven metal-dependent HDACs, representing classes I, II and 
IV, at a fixed concentration (Table 2). As a negative control, an N-methylhydroxamic acid, 60, 
was prepared and assessed in parallel. The synthetic route is described in Scheme 2. Briefly, 
starting from O-benzylhydroxylamine (55), Boc-protection of the amino group was followed by 
methylation and acid-mediated removal of the Boc group to furnish O-benzyl-N-
methylhydroxylamine (58). Coupling of this compound with 37, followed by hydrogenation, as 
previously described, yielded 60. 
 
Scheme 2: Synthesis of N-methylhydroxamic acid 60 
 
(a) Boc2O, THF, 24 h, RT; (b) MeI, NaH (60%), DMF, 24 h, RT; (c) (i) CF3CO2H/CHCl3 (1:3), 22 h, RT; (ii) 1M 
NaOH; (d) (i) (COCl)2, THF, DMF, 2 h, 0 °C, N2; (ii) 58, iPr2NEt, THF, 16 h, RT, N2; (e) H2, 10% Pd/C, THF/MeOH 
(2:1), 16 h, RT. 
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AES-135 and control compound 60 were screened against full recombinant human HDACs 1, 3, 
4, 6, 8, 10 and 11 using an electrophoretic mobility shift assay (EMSA) at 10 µM. AES-135 
inhibited HDACs 3, 6, 8 and 11 (>90%), and showed moderate inhibition of HDACs 1 and 10 
(≥70%), with HDAC4 not being affected (<20%). HDAC inhibition was highly sensitive to 
modification of the hydroxamic acid motif, with compound 60 demonstrating only modest 
inhibition of HDAC11 (64%), but negligible activity against the remaining HDACs (Table 2). 
 
Table 2. Percentage Inhibition of HDACs 1, 3, 4, 6, 8, 10 and 11 by AES-135 and 60 at 10 µM 
(EMSA, n=2) 
HDAC 
%-Inhibition 
AES-135 60 
1 72 0 
0 
0 
12 
0 
0 
64 
3 98 
4 15 
6 98 
8 94 
10 70 
11 97 
 
To evaluate in vitro stability, AES-135 and 8 were incubated with mouse hepatocytes for 2 h to 
assess the rate of intrinsic clearance. The calcium channel blocker Verapamil was used as a positive 
control. AES-135 reported an intrinsic clearance rate of 36.0 µL/min/106 cells; almost half the rate 
of Verapamil (63.3 µL/min/106 cells), and a half-life of 38.5 min, which was almost twice that of 
Verapamil (21.9 min) (Supporting Information, Table S4, Figure S15 – S20). Derivative 8, 
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possessing a CF3 in the R1 position, performed similarly to AES-135 (R1 = t-Bu), returning a 
clearance rate of 37.4 µL/min/106 cells and a half-life of 37.1 min, suggesting that the t-Bu group 
of AES-135 was not being targeted for oxidation in mouse hepatocytes. The observed stability of 
AES-135 supported the in vitro findings that the PFB ring was a relatively stable substituent. A 
protein binding study using AES-135 in mouse plasma found that the compound was 99.6% bound 
after 6 h incubation. The low recovery (16 – 20%) of AES-135 after this time indicated the 
compound to be susceptible to metabolism in plasma (Supporting Information, Table S5). In a 
separate study, the experimental LogD7.4 for AES-135 was calculated using a 1-octanol/PBS 
system, returning a value of 4.15 (Supporting Information, Table S6).  
To investigate the permeability profile of AES-135 and 8 through the blood brain barrier (BBB), 
the compounds were tested using a parallel artificial membrane permeability assay (PAMPA), 
which assesses the ability of a compound to cross a lipid-infused artificial membrane, and has been 
shown to correlate well with performance in crossing in vivo barriers. Testosterone and the 
antimetabolite Methotrexate were used as positive and negative controls, respectively. In this 
assay, a permeability coefficient (-Log Pe) <6 defined the compound as having high permeability 
through a lipid membrane, whereas a -Log Pe >6 meant the compound had low permeability. 
Results from this assay showed that AES-135 and 8 were poorly permeable compounds, returning 
-Log Pe values of 7.73 and 7.02, respectively. By comparison, testosterone gave a value of 4.61 
and Methotrexate >8.5, where the degree of membrane permeation was below the limit of detection 
(Supporting Information, Table S7 – S11). The results indicated that AES-135 would be poorly 
efficacious against cancers surrounded by undamaged membranes, e.g. GBM, despite impressive 
in vitro potency. 
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AES-135 was also analyzed in a Caco-2 assay to gauge its permeability through a monolayer of 
tightly packed epithelial cells; an in vitro model of the human small intestinal membrane. The 
Caco-2 cells also express several transporter proteins, e.g. P-glycoprotein (P-gp), and can thus 
provide information on the efflux rate of compounds from a cell. Propranolol, Digoxin and 
Prazosin were used as controls with low, high and medium efflux rates, respectively. Results from 
this assay supported those from the PAMPA, showing AES-135 to have poor permeation through 
the monolayer, with an apparent permeability coefficient, Papp (A-B), of 0.27 x 10-6 cm/s. 
Compared to Propranolol and Prazosin, with respective Papp (A-B) values of 15.41 and 19.94 x 10-
6 cm/s, AES-135 was significantly less permeable. In addition, the Papp (B-A) for AES-135 was 
1.02 x 10-6 cm/s, calculating an efflux ratio of 3.83 (Supporting Information, Table S12 – S13). 
This suggested that AES-135 was transported out of the cell approximately 4-fold faster than it 
was being absorbed, meaning that it would struggle to achieve suitable intestinal absorption in vivo 
if administered orally. The data also indicated that, despite potent in vitro activity, AES-135 would 
not be efficacious if used to treat cancers requiring penetration of bone marrow, e.g. AML. 
To assess the pharmacokinetic properties of AES-135 in vivo, NSG mice were dosed with a single 
20 mg/Kg intraperitoneal (IP) injection, and blood was taken at 0.5, 1, 2, 4, 8 and 24 h. AES-135 
achieved µM concentrations in the blood, reaching Cmax 7,452 ng/mL (10.74 µM) within 30 min, 
which was sustained for 8 h, with significant clearance observed only after 24 h (Table 3). In these 
mice, AES-135 had a calculated half-life of 5.0 h, with a clearance rate of 0.004 L/h, assuming 
bioavailability to be 100% (Supporting Information, Table S14 – S15). 
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Table 3. Serum Concentrations of AES-135 Following One Dose at 20 mg/Kg, IP (n=2) 
Time (h) [AES-135] (ng/mL) 
0.5 7452 ± 1354 
1 5397 ± 1079 
2 5391 ± 2418 
4 3655 ± 400 
8 6392 ± 222 
24 265 ± 29 
 
In a follow-up study, AES-135 was administered at 10 mg/Kg and 40 mg/Kg, once a day for five 
days. Blood was collected from each mouse 5 h following the final injection (Figure 2A). 
Encouragingly, the results showed that the blood concentration of AES-135 was dose-dependent, 
achieving an average of 323 ng/mL (0.47 µM) with 10 mg/Kg dosing, and 1829 ng/mL (2.64 µM) 
with 40 mg/Kg. No visible toxicity associated with either dose, based on percentage weight loss 
compared to vehicle control, was observed. This represents an approximate 5.7-fold increase in 
blood concentration from quadrupling the dose. 
 
To evaluate AES-135 toxicity in vivo, NSG mice were dosed by IP daily with a range of 
concentrations for 4 – 5 days (n=6). Mice were weighed prior to, and following, administration of 
the compound and toxicity assessed via weight loss (Figure 2B). At 60 mg/Kg, the mice showed 
no significant weight loss, indicating AES-135 to be non-toxic at the highest concentration. 
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Figure 2A. Serum concentrations of AES-135 in NSG mice following 10 and 40 mg/Kg injections 
daily for 5 days, IP (n=6, ±SD); Figure 2B. Toxicity study with AES-135 in NSG mice 
administered over 5 days, IP (n=6, ±SD). 
 
AES-135 was consistently cytotoxic in multiple low-passage patient-derived pancreatic cancer cell 
lines, namely Pa03C, Pa02C and Panc10.05 cells (the latter hereto referred as 10.05). IC50 values 
were in the low µM range (1 – 4 µM) in monolayer proliferation-based assays of these tumor lines. 
The efficacy of AES-135 was also assessed in KPC tumor cells, which are derived from the ‘gold 
standard’ genetically engineered mouse model of PDAC (KrasLSL.G12D/+; Trp53R172H/+; Elas-
CreER).41 Interestingly, the tumor cells generated from the KPC42 genetically engineered PDAC 
mouse model were extremely sensitive to AES-135 and had an IC50 of 1.3 µM in the monolayer, 
compared to 8.5 µM for the pan-HDAC inhibitor Panobinostat, which was used as a positive 
control (Figure 3).  KPC mice develop premalignant lesions called Pancreatic Intraepithelial 
Neoplasia (PanINs), which progress to visible carcinomas with 100% penetrance, and display a 
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morphology similar to that observed in human PDAC. Metastases arise in 80% of KPC mice, 
primarily in the liver and lungs; the most common metastatic sites in humans. The KPC tumors 
possess intricate genomic rearrangements; a sign of genomic instability, making this one of the 
most aggressive PDAC models used in preclinical research. They are notoriously resistant to 
standard-of-care therapy; only 12% of tumors demonstrate sensitivity towards gemcitabine.43 
 
Figure 3.  Dose-dependent reduction by A) AES-135 and B) Panobinostat, in cell proliferation in 
pancreatic cancer cells in monolayer. Average of at least three experiments + SE. 
 
Next, we evaluated the efficacy of AES-135 in preclinical predictive 3D tumor models of 
pancreatic cancer using patient-derived tumor cells as well as CAFs. Pancreatic cancers are 
difficult to treat effectively, in part because of the CAFs that surround the tumor and impede access 
by chemotherapeutics. Additionally, CAFs facilitate tumor growth through the secretion of growth 
factors, e.g. VEGF, IL-6, and TGF-β, promoting invasion and metastasis.47 AES-135 reduced 
pancreatic tumor spheroids, even with a protective CAF microenvironment, and showed 5- to 6-
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fold greater selectivity for the tumor cells over the CAFs (Figure 4). Single-digit µM to high nM 
potencies were demonstrated in the analogous 3D tumor models, both in reducing tumor area and 
intensity (Table 4).  
 
Figure 4. Dose-dependent reduction in tumor spheroid intensity in patient-derived pancreatic 
cancer cells Pa03C (red, n=3, ±SE) and 10.05 (blue, n=3, ±SE); Fold change compares the treated 
tumor only spheroids to media control. 
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Table 4. IC50 Values for AES-135 in Several Monolayer and 3D Human-Derived PDAC Cell 
Lines (n = 3 – 5) 
Monolayer PDAC Cells 
Cell Line IC50 (µM) 
Pa02C 4.6 
Pa03C 3.4 
10.05 3.9 
KPC 1.3 
 
 
 
 
 
 
aArea: the µ2 of objects which exceed a minimum tomato red intensity threshold in the well; bthe sum of all intensity 
values for pixels marked as Ch2 objects (i.e. total red OR green fluorescence in the well, after background removal). 
 
Due to the high sensitivity of the KPC cells to AES-135 treatment, we tested the in vivo potency 
of AES-135 in a syngeneic orthotopic model. KPC cells were orthotopically implanted in the 
pancreas of C57Bl/6 mice, which were subsequently treated with either 50 mg/kg AES-135 or 
vehicle control. A murine mouse model was utilized in the in vivo studies due to the role of HDACs 
in the modulation of immune cell function.44-45 Furthermore, in lung and renal cell carcinoma 
3D PDAC Cells 
Cell Line Scan Type IC50 (µM) 
Pa03C Areaa 1.22 
Pa03C + CAFs Area 1.41 
CAF co-culture Area 7.80 
Pa03C Intensityb 1.33 
Pa03C + CAFs Intensity 1.56 
CAF co-culture Intensity 4.50 
10.05 Area 0.97 
10.05 + CAFs Area 0.94 
CAF co-culture Area 4.70 
10.05 Intensity 0.60 
10.05 + CAFs Intensity 0.50 
CAF co-culture Intensity 3.40 
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mouse models, HDAC inhibitor Entinostat (SNDX-275; MS-275) potentiated the effects of PD-1 
inhibition, and this effect was partially mediated by functional inhibition of MDSCs.45 HDAC 
inhibitors would be effective in blockading tumor cell proliferation and cell cycle progression, and 
also have immunomodulatory effects.46-47 Mice treated with AES-135 showed significantly 
increased survival, with a median survival rate of 36.5 days compared to 29.5 days for the vehicle 
mice (Figure 5, p=0.0146). The ability to provide a survival advantage in this aggressive PDAC 
model illustrates the potential of AES-135 as a hit-to-lead compound. This effect was only 
observed in immunocompetent mice; the equivalent immunodeficient mice showed no obvious 
survival advantage (Supporting Information, Figure S21). 
 
 
Figure 5. Increased survival of C57Bl/6 mice implanted with KPC tumor cells, following AES-
135 treatment. Mice treated with 50 mg/Kg AES-135, IP daily (blue, n=10) exhibited a statistically 
significant survival advantage compared to mice treated with vehicle (green, n=10), p = 0.0146 
(Log-Rank test). Treatment started on Day 7 with a cycle of 5 days on, 2 days off and continued 
until Day 36. 
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Conclusion 
Several reviews have described the potential of HDAC inhibitors to effectively treat PDAC,48-51 
but to date, no compound has been published demonstrating suitable potency and drug-like 
properties against this aggressive disease. We have presented a set of structurally novel 
hydroxamic acid-containing molecules displaying nM inhibition of HDACs in a target-based 
assay. Lead compound, AES-135, demonstrated potent inhibition of HDACs 3, 6, 8 and 11, and 
high cytotoxicity in a variety of cancer cell lines, most notably in pancreatic tumor lines. AES-135 
was consistently more active in PDAC tumor models, both monolayer and 3D, than STAT 
inhibitor 1, even showing single-digit µM IC50 values in the highly aggressive KPC model, which 
was superior to the FDA-approved HDAC inhibitor Panobinostat. AES-135 showed an impressive 
PK profile in mice, with an in vivo half-life of 5.0 h, prolonged blood concentration above its IC50 
value, and unremarkable toxicity, as assessed by a brief study. Subsequent in vivo evaluation in 
immunocompetent mice found that AES-135 extended the life of the mice significantly. To 
effectively treat pancreatic cancer, single agent therapy has not been effective, therefore 
individualized combinations of targeted therapies will be necessary for making therapeutic 
advances in this devastating disease. Combination studies including AES-135 in animal models 
are crucial in order to determine whether the addition of HDAC inhibitors to standard of care 
agents or new combination, such as immune checkpoint inhibitors, will dramatically extend 
survival.  NMR and X-ray crystallographic studies are ongoing to determine the exact binding 
mechanism of AES-135 with HDACs to identify more potent and selective binding agents for 
preclinical evaluation.  
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Experimental Section 
Materials and Methods. A 400 MHz Bruker NMR was utilized to obtain 1H, 13C, and 19F 
NMR spectra in CDCl3 (99.8 atom% D), CD3CN (99.8 atom% D), or MeOH-d4 (99.8 atom% D), 
as indicated (1H at 400 MHz, 13C at 100 MHz, and 19F at 54 MHz). Chemical shifts (δ) are reported 
in parts per million (ppm), after calibration to residual isotopic solvent, and coupling constants (J) 
are reported in Hertz (Hz). Low-resolution mass spectrometry (LRMS) was carried out using a 
Waters LC-MS in ESI mode, fitted with a Micromass ZQ MS and an Alliance 2690 LC. High-
resolution mass spectrometry (HRMS) was carried out using an Agilent 6538 UHD Q-TOF MS in 
ESI mode with a mass accuracy +/- 1 mDa. Thin Layer Chromatography (TLC) was conducted on 
Merck silica gel 60F254 on aluminium sheets. All sheets were dried after use and visualized using 
short wave (254 nm) and long wave (365 nm) UV light and/or staining with KMnO4. Column 
chromatography was carried out at room temperature using Biotage Isolera One and Isolera Prime 
purification systems, with industry-standard SNAP cartridges loaded with 40–60 µm silica gel 
(average pore size 60Å). Semi-preparative HPLC was conducted using a Waters 2487 Dual λ 
Absorbance Detector, equipped with a Symmetry® C18 4.6 mm x 150 mm cartridge. Inhibitor 
purity was evaluated at room temperature by a Hewlett Packard Series 1100 analytical HPLC 
system fitted with a Phenomenex Luna 5.0 µm C18 4.6 mm x 150 mm cartridge, using gradient 
mixtures of (A) MilliQ water with 0.1% (v/v) TFA and (B) HPLC-grade acetonitrile. Biologically 
evaluated compounds are ≥ 95% chemically pure, as measured by HPLC. Chemicals and solvents 
were purchased from Sigma-Aldrich (MilliporeSigma), VWR International, Alfa Aesar, Combi-
Blocks, Caledon Laboratory Chemicals and Promega, and were used as supplied. 
 General Procedure for the Synthesis of Compounds AES-135, 2 – 8, 36 – 43, and 60. 
The benzyl or hydroxamate ester (1.0 equiv.) was dissolved in THF/methanol (2:1) (0.1 M) and 
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purged with nitrogen. 10% Pd/C (0.04 equiv.) was added after 15 min and the flask was purged 
with hydrogen for 10 min. The reaction was allowed to stir at RT under hydrogen. After 16 h, the 
reaction was filtered through celite, washing with EtOAc, and concentrated in vacuo. Semi-
preparative HPLC, followed by lyophilization at -50 °C, isolated the target compound. 
 4-(N-(4-(tert-butyl)benzyl)-2-((4-fluoro-N-
((perfluorophenyl)methyl)phenyl)sulfonamido)acetamido)-N-hydroxybenzamide (AES-
135). Semi-preparative HPLC using acetonitrile/0.1% (v/v) TFA in MilliQ water (0:1 à 1:0, 50 
min à 10 min) eluted the target compound at 42.8 – 44.0 min. The product was suspended in 
acetonitrile/MilliQ water (1:3, 4 mL) and lyophilized overnight at -50 °C to give AES-135 as a 
white solid (52.2 mg, 56%); 1H δ/ppm (400 MHz, CDCl3) 1.29 (s, 9H, tBu), 3.86 (s, 2H, CH2), 
4.61 (s, 2H, CH2), 4.73 (s, 2H, CH2), 6.97 (d, J = 7.8 Hz, 2H, 2 CH), 7.08 (d, J = 7.3 Hz, 2H, 2 
CH), 7.14 (t, J = 8.5 Hz, 2H, 2 CH), 7.27 (d, J = 7.9 Hz, 2H, 2 CH), 7.75 (d, J = 7.1 Hz, 2H, 2 
CH), 7.83 – 7.87 (m, 2H, 2 CH), hydroxamic acid NH and OH protons were not observed; 13C 
δ/ppm (100 MHz, CDCl3) 31.1, 34.4, 39.6, 49.2, 53.0, 101.4, 115.9, 116.1, 124.4, 125.4, 128.3, 
128.7, 130.3, 130.4, 132.8, 134.87, 134.91, 143.8, 144.2, 146.8, 150.9, 163.9, 164.8, 166.2, 166.5; 
19F δ/ppm (54 MHz, CDCl3) -162.3 (td, J = 6.1 and 20.9 Hz, 2F), -153.9 (t, J = 20.5 Hz, 1F), -
142.2 (dd, J = 7.0 and 22.5 Hz, 2F), -105.4 to -105.3 (m, 1F); LRMS (ESI+) m/z calcd for 
[C33H30F6N3O5S]+: 694.67, found: 694.36; calcd for [C33H29F6N3O5SNa]+: 716.65, found: 716.34; 
HRMS (ESI+) m/z calcd for [C33H30F6N3O5S]+: 694.1798, found: 694.1805; HPLC (I) tR = 23.55 
min (97.9%); HPLC (II) tR = 38.44 min (99.9%). 
 4-(N-(4-(tert-butyl)benzyl)-2-((3,4-difluoro-N-(2-
(trifluoromethyl)benzyl)phenyl)sulfonamido)acetamido)-N-hydroxybenzamide (2). Semi-
preparative HPLC using acetonitrile/0.1% (v/v) TFA in MilliQ water (0:1 à 1:0, 50 min à 10 
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min) eluted the target compound at 42.1 – 43.6 min. The product was suspended in 
acetonitrile/MilliQ water (1:3, 4 mL) and lyophilized overnight at -50 °C to give 2 as a white solid 
(83.9 mg, 68%); 1H δ/ppm (400 MHz, CDCl3) 1.29 (s, 9H, tBu), 3.68 (s, br, 2H, CH2), 4.70 (s, 2H, 
CH2), 4.74 (s, 2H, CH2), 6.90 (d, J = 7.3 Hz, 2H, 2 CH), 6.94 (d, J = 8.1 Hz, 2H, 2 CH), 7.26 (d, J 
= 8.2 Hz, 2H, 2 CH), 7.30 (d, J = 8.3 Hz, 1H, CH), 7.36 (t, J = 8.3 Hz, 1H, CH), 7.46 (t, J = 7.4 
Hz, 1H, CH), 7.61 – 7.77 (m, 6H, 6 CH), hydroxamic acid NH and OH protons were not observed; 
13C δ/ppm (100 MHz, CDCl3) 31.3, 34.5, 47.4, 48.0, 53.1, 117.7, 117.87, 117.90, 118.0, 122.7, 
124.87, 124.91, 124.94, 125.0, 125.4, 125.5, 125.75, 125.81, 125.86, 125.92, 128.0, 128.4, 128.5, 
128.65, 128.74, 130.1, 132.5, 132.9, 134.1, 136.5, 143.9, 148.8, 151.0, 151.9, 165.8, 166.0; 19F 
δ/ppm (54 MHz, CDCl3) -134.0 (dt, J = 8.5 and 20.7 Hz, 1F), -129.3 to -129.1 (m, 1F), -59.1 (s, 
3F); LRMS (ESI+) m/z calcd for [C34H33F5N3O5S]+: 690.71, found: 690.45; calcd for 
[C34H32F5N3O5SNa]+: 712.69, found: 712.43; HRMS (ESI+) m/z calcd for [C34H33F5N3O5S]+: 
690.2064, found: 690.2056; HPLC (I) tR = 24.65 min (99.9%); HPLC (II) tR = 40.23 min (99.9%). 
 4-(2-((3,4-difluoro-N-(2-(trifluoromethyl)benzyl)phenyl)sulfonamido)-N-(4-
(trifluoromethyl)benzyl)acetamido)-N-hydroxybenzamide (3). Semi-preparative HPLC using 
acetonitrile/0.1% (v/v) TFA in MilliQ water (0:1 à 1:0, 50 min à 10 min) eluted the target 
compound at 37.9 – 39.4 min. The product was suspended in acetonitrile/MilliQ water (1:3, 4 mL) 
and lyophilized overnight at -50 °C to give 3 as a white solid (82.2 mg, 71%); 1H δ/ppm (400 MHz, 
CDCl3) 3.70 (s, 2H, CH2), 4.71 (s, 2H, CH2), 4.79 (s, 2H, CH2), 6.91 (d, J = 7.6 Hz, 2H, 2 CH), 
7.17 (d, J = 7.9 Hz, 2H, 2 CH), 7.29 – 7.33 (m, 1H, CH), 7.37 (t, J = 7.7 Hz, 1H, CH), 7.47 (t, J = 
7.7 Hz, 1H, CH), 7.51 (d, J = 8.1 Hz, 2H, 2 CH), 7.61 – 7.76 (m, 6H, 6 CH), 9.19 (s, br, 1H, NH), 
hydroxamic acid OH proton was not observed; 13C δ/ppm (100 MHz, CDCl3) 47.4, 48.0, 52.9, 
117.6, 117.8, 117.9, 118.1, 122.6, 122.7, 124.8, 124.87, 124.91, 125.0, 125.3, 125.4, 125.57, 
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125.59, 125.63, 125.7, 125.8, 125.9, 128.2, 128.3, 128.5, 128.6, 128.9, 129.0, 130.2, 130.4, 131.2, 
132.6, 133.9, 136.5, 140.0, 143.5, 151.2, 165.2, 166.4; 19F δ/ppm (54 MHz, CDCl3) -133.9 (dt, J 
= 8.7 and 20.6 Hz, 1F), -129.0 to -128.9 (m, 1F), -62.6 (s, 3F), -59.0 (s, 3F); LRMS (ESI+) m/z 
calcd for [C31H24F8N3O5S]+: 702.60, found: 702.36; calcd for [C31H23F8N3O5SNa]+: 724.58, 
found: 724.34; HRMS (ESI+) m/z calcd for [C31H24F8N3O5S]+: 702.1308, found: 702.1303; HPLC 
(I) tR = 23.11 min (99.9%); HPLC (II) tR = 37.67 min (99.9%). 
 4-(N-(4-(tert-butyl)benzyl)-2-((2,4-difluoro-N-(2-
(trifluoromethyl)benzyl)phenyl)sulfonamido)acetamido)-N-hydroxybenzamide (4). Semi-
preparative HPLC using acetonitrile/0.1% (v/v) TFA in MilliQ water (0:1 à 1:0, 50 min à 10 
min) eluted the target compound at 42.0 – 43.7 min. The product was suspended in 
acetonitrile/MilliQ water (1:3, 4 mL) and lyophilized overnight at -50 °C to give 4 as a white solid 
(57.4 mg, 69%); 1H δ/ppm (400 MHz, CDCl3) 1.29 (s, 9H, tBu), 3.72 (s, 2H, CH2), 4.68 (s, 2H, 
CH2), 4.88 (s, 2H, CH2), 6.91 – 6.98 (m, 6H, 6 CH), 7.24 (d, J = 8.2 Hz, 2H, 2 CH), 7.34 (t, J = 
7.6 Hz, 1H, CH), 7.46 (t, J = 7.5 Hz, 1H, CH), 7.60 – 7.66 (m, 4H, 4 CH), 7.85 – 7.91 (m, 1H, 
CH), 9.14 (s, br, 1H, NH), hydroxamic acid OH proton was not observed; 13C δ/ppm (100 MHz, 
CDCl3) 31.3, 34.5, 47.7, 48.0, 53.0, 105.5, 105.7, 106.0, 111.4, 111.6, 124.7, 125.4, 125.5, 125.7, 
125.75, 125.81, 125.9, 127.9, 128.4, 128.5, 128.6, 128.7, 128.75, 128.77, 128.84, 130.1, 131.8, 
131.9, 132.5, 133.1, 134.7, 144.0, 150.9, 164.1, 164.6, 165.4; 19F δ/ppm (54 MHz, CDCl3) -101.3 
to -101.2 (m, 1F), -100.7 to -100.6 (m, 1F), -59.1 (s, 3F); LRMS (ESI+) m/z calcd for 
[C34H32F5N3O5SNa]+: 712.69, found: 712.56; HRMS (ESI+) m/z calcd for [C34H33F5N3O5S]+: 
690.2063, found: 690.2056; HPLC (I) tR = 24.11 min (95.3%); HPLC (II) tR = 39.18 min (98.8%). 
 4-(2-((2,4-difluoro-N-(2-(trifluoromethyl)benzyl)phenyl)sulfonamido)-N-(4-
(trifluoromethyl)benzyl)acetamido)-N-hydroxybenzamide (5). Semi-preparative HPLC using 
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acetonitrile/0.1% (v/v) TFA in MilliQ water (0:1 à 1:0, 50 min à 10 min) eluted the target 
compound at 38.3 – 40.1 min. The product was suspended in acetonitrile/MilliQ water (1:3, 4 mL) 
and lyophilized overnight at -50 °C to give 5 as a white solid (95.2 mg, 80%); 1H δ/ppm (400 MHz, 
CDCl3) 3.74 (s, 2H, CH2), 4.77 (s, 2H, CH2), 4.85 (s, 2H, CH2), 6.92 – 6.99 (m, 4H, 4 CH), 7.14 
(d, J = 8.0 Hz, 2H, 2 CH), 7.35 (t, J = 7.6 Hz, 1H, CH), 7.46 (t, J = 7.6 Hz, 1H, CH), 7.49 (d, J = 
8.2 Hz, 2H, 2 CH), 7.59 – 7.66 (m, 4H, 4 CH), 7.86 – 7.91 (m, 1H, CH), hydroxamic acid NH and 
OH protons were not observed; 13C δ/ppm (100 MHz, CDCl3) 47.6, 48.0, 52.9, 105.4, 105.7, 105.9, 
111.45, 111.49, 111.68, 111.71, 122.8, 124.58, 124.62, 124.7, 124.8, 125.3, 125.5, 125.7, 125.78, 
125.83, 125.9, 127.3, 128.0, 128.6, 128.7, 128.97, 129.00, 130.2, 131.8, 131.9, 132.0, 132.5, 134.4, 
140.1, 143.6, 161.6, 164.5, 166.3, 167.1; 19F δ/ppm (54 MHz, CDCl3) -101.6 to -101.5 (m, 1F), -
100.3 to -100.2 (m, 1F), -62.6 (s, 3F), -59.0 (s, 3F); LRMS (ESI+) m/z calcd for [C31H24F8N3O5S]+: 
702.60, found: 702.48; calcd for [C31H23F8N3O5SNa]+: 724.58, found: 724.40; HRMS (ESI+) m/z 
calcd for [C31H24F8N3O5S]+: 702.1307, found: 702.1303; HPLC (I) tR = 22.62 min (99.9%); HPLC 
(II) tR = 36.62 min (97.2%). 
 4-(N-(4-(tert-butyl)benzyl)-2-((4-fluoro-N-(2-
(trifluoromethyl)benzyl)phenyl)sulfonamido)acetamido)-N-hydroxybenzamide (6). Semi-
preparative HPLC using acetonitrile/0.1% (v/v) TFA in MilliQ water (0:1 à 1:0, 50 min à 10 
min) eluted the target compound at 41.0 – 42.5 min. The product was suspended in 
acetonitrile/MilliQ water (1:3, 4 mL) and lyophilized overnight at -50 °C to give 6 as a white solid 
(90.4 mg, 68%); 1H δ/ppm (400 MHz, CDCl3) 1.29 (s, 9H, tBu), 3.69 (s, 2H, CH2), 4.69 (s, 2H, 
CH2), 4.75 (s, 2H, CH2), 6.91 (d, J = 8.0 Hz, 2H, 2 CH), 6.94 (d, J = 8.2 Hz, 2H, 2 CH), 7.18 (t, J 
= 8.5 Hz, 2H, 2 CH), 7.25 (d, J = 8.2 Hz, 2H, 2 CH), 7.34 (t, J = 7.6 Hz, 1H, CH), 7.45 (t, J = 7.6 
Hz, 1H, CH), 7.62 (t, J = 7.8 Hz, 2H, 2 CH), 7.66 (d, J = 8.0 Hz, 2H, 2 CH), 7.90 – 7.94 (m, 2H, 
Page 27 of 57
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
28 
 
2 CH), 9.14 (s, br, 1H, NH), hydroxamic acid OH proton was not observed; 13C δ/ppm (100 MHz, 
CDCl3) 31.3, 34.5, 47.5, 47.9, 53.0, 116.0, 116.2, 125.5, 125.7, 125.76, 125.81, 125.9, 127.9, 
128.0, 128.3, 128.5, 128.6, 128.7, 130.0, 130.5, 130.6, 130.7, 132.5, 133.0, 134.45, 134.47, 135.7, 
135.8, 150.9, 164.0, 166.13, 166.16, 166.5; 19F δ/ppm (54 MHz, CDCl3) -104.84 to -104.77 (m, 
1F), -59.2 (s, 3F); LRMS (ESI+) m/z calcd for [C34H34F4N3O5S]+: 672.72, found: 672.50; calcd for 
[C34H33F4N3O5SNa]+: 694.70, found: 694.42; HRMS (ESI+) m/z calcd for [C34H34F4N3O5S]+: 
672.2157, found: 672.2150; HPLC (I) tR = 23.66 min (99.9%); HPLC (II) tR = 38.58 min (99.9%). 
 4-(2-((4-fluoro-N-(2-(trifluoromethyl)benzyl)phenyl)sulfonamido)-N-(4-
(trifluoromethyl)benzyl)acetamido)-N-hydroxybenzamide (7). Semi-preparative HPLC using 
acetonitrile/0.1% (v/v) TFA in MilliQ water (0:1 à 1:0, 50 min à 10 min) eluted the target 
compound at 37.1 – 38.6 min. The product was suspended in acetonitrile/MilliQ water (1:3, 4 mL) 
and lyophilized overnight at -50 °C to give 7 as a white solid (87.9 mg, 77%); 1H δ/ppm (400 MHz, 
CDCl3) 3.70 (s, 2H, CH2), 4.73 (s, 2H, CH2), 4.79 (s, 2H, CH2), 6.91 (d, J = 7.6 Hz, 2H, 2 CH), 
7.15 (d, J = 8.5 Hz, 2H, 2 CH), 7.19 (t, J = 8.5 Hz, 2H, 2 CH), 7.35 (t, J = 7.6 Hz, 1H, CH), 7.45 
(t, J = 7.6 Hz, 1H, CH), 7.49 (d, J = 8.1 Hz, 2H, 2 CH), 7.61 (d, J = 8.5 Hz, 2H, 2 CH), 7.65 (d, J 
= 8.2 Hz, 2H, 2 CH), 7.90 – 7.94 (m, 2H, 2 CH), hydroxamic acid NH and OH protons were not 
observed; 13C δ/ppm (100 MHz, CDCl3) 47.4, 47.9, 52.9, 116.1, 116.3, 122.7, 125.3, 125.47, 
125.53, 125.57, 125.64, 125.8, 125.85, 125.88, 128.0, 128.3, 128.5, 128.6, 128.9, 128.97, 129.00, 
130.1, 130.4, 130.5, 132.5, 134.2, 135.66, 135.69, 140.1, 143.7, 164.0, 166.55, 166.64; 19F δ/ppm 
(54 MHz, CDCl3) -104.6 to -104.5 (m, 1F), -62.6 (s, 3F), -59.0 (s, 3F); LRMS (ESI+) m/z calcd 
for [C31H24F7N3O5SNa]+: 706.59, found: 706.33; HRMS (ESI+) m/z calcd for [C31H25F7N3O5S]+: 
684.1399, found: 684.1398; HPLC (I) tR = 22.20 min (99.9%); HPLC (II) tR = 36.13 min (97.1%). 
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 4-(2-((4-fluoro-N-((perfluorophenyl)methyl)phenyl)sulfonamido)-N-(4-
(trifluoromethyl)benzyl)acetamido)-N-hydroxybenzamide (8). Semi-preparative HPLC using 
acetonitrile/0.1% (v/v) TFA in MilliQ water (0:1 à 1:0, 50 min à 10 min) eluted the target 
compound at 37.3 – 37.9 min. The product was suspended in acetonitrile/MilliQ water (1:3, 4 mL) 
and lyophilized overnight at -50 °C to give 8 as a white solid (14.0 mg, 46%); 1H δ/ppm (400 MHz, 
CDCl3) 3.85 (s, 2H, CH2), 4.60 (s, 2H, CH2), 4.84 (s, 2H, CH2), 7.10 (d, J = 7.8 Hz, 2H, 2 CH), 
7.16 (t, J = 8.5 Hz, 2H, 2 CH), 7.21 (d, J = 7.8 Hz, 2H, 2 CH), 7.52 (d, J = 8.0 Hz, 2H, 2 CH), 7.77 
(d, J = 7.7 Hz, 2H, 2 CH), 7.84 (dd, J = 5.1 and 8.6 Hz, 2H, 2 CH), hydroxamic acid NH and OH 
protons were not observed; 13C δ/ppm (100 MHz, CDCl3) 39.7, 49.3, 53.0, 109.7, 116.1, 116.3, 
125.6, 125.65, 125.71, 125.74, 128.6, 128.7, 129.00, 129.04, 129.07, 129.09, 130.1, 130.4, 130.5, 
131.1, 133.6, 135.0, 135.1, 140.0, 143.6, 164.1, 165.1, 166.7, 166.8; 19F δ/ppm (54 MHz, CDCl3) 
-161.1 (td, J = 7.4 and 21.5 Hz, 2F), -152.5 (t, J = 20.9 Hz, 1F), -141.3 (dd, J = 8.0 and 22.2 Hz, 
2F), -104.1 to -104.0 (m, 1F), -62.6 (s, 3F); LRMS (ESI-) m/z calcd for [C30H19F9N3O5S]-: 704.54, 
found: 704.35; HRMS (ESI+) m/z calcd for [C30H21F9N3O5S]+: 706.1053, found: 706.1044; HPLC 
(I) tR = 21.96 min (99.9%); HPLC (II) tR = 35.74 min (99.9%). 
 4-(N-(4-(tert-butyl)benzyl)-2-((4-fluoro-N-
((perfluorophenyl)methyl)phenyl)sulfonamido)acetamido)-N-hydroxy-N-methylbenzamide 
(60). Semi-preparative HPLC using acetonitrile/0.1% (v/v) TFA in MilliQ water (0:1 à 1:0, 50 
min à 10 min) eluted the target compound at 47.2 – 48.4 min. The product was suspended in 
acetonitrile/MilliQ water (1:3, 2 mL) and lyophilized overnight at -50 °C to give 60 as a white 
solid (19.1 mg, 77%); 1H δ/ppm (400 MHz, CDCl3) 1.31 (s, 9H, tBu), 3.42 (s, 3H, CH3), 3.87 (s, 
2H, CH2), 4.61 (s, 2H, CH2), 4.75 (s, 2H, CH2), 6.99 (d, J = 8.0 Hz, 2H, 2 CH), 7.09 (d, J = 7.8 
Hz, 2H, 2 CH), 7.17 (t, J = 8.6 Hz, 2H, 2 CH), 7.29 (d, J = 8.0 Hz, 2H, 2 CH), 7.57 (d, J = 8.2 Hz, 
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2H, 2 CH), 7.85 – 7.89 (m, 2H, 2 CH), hydroxamic acid OH proton was not observed; 13C δ/ppm 
(100 MHz, CDCl3) 31.3, 34.6, 38.0, 39.7, 49.5, 53.2, 116.0, 116.2, 125.5, 127.9, 128.5, 128.56, 
128.61, 129.9, 130.5, 130.6, 132.5, 133.0, 135.2, 151.0, 161.1, 164.1, 166.4, 167.2; 19F δ/ppm (54 
MHz, CDCl3) -161.3 (td, J = 7.4 and 21.7 Hz, 2F), -151.9 (t, J = 21.0 Hz, 1F), -141.1 (dd, J = 7.7 
and 22.4 Hz, 2F), -104.5 to -104.4 (m, 1F); LRMS (ESI+) m/z calcd for [C34H32F6N3O5S]+: 708.70, 
found: 708.25; calcd for [C34H31F6N3O5SNa]+: 730.68, found: 730.25; (ESI-) m/z calcd for 
[C34H30F6N3O5S]-: 706.68, found: 706.36; HRMS (ESI+) m/z calcd for [C34H32F6N3O5S]+: 
708.1969, found: 708.1961; HPLC (I) tR = 24.49 min (99.9%); HPLC (II) tR = 40.09 min (99.9%). 
General Procedure for the Synthesis of Compound 10. The appropriate benzoic acid 
(1.0 equiv.) and cesium carbonate (1.2 equiv.) were suspended in DMF (0.7 M) and stirred at RT 
for 20 min in air, before addition of benzyl bromide (1.0 equiv.) in one go, and the reaction was 
stirred at RT. After 24 h, the solvent was removed in vacuo at 80 oC and the resulting solid was 
partitioned using EtOAc with saturated aqueous NaHCO3 and distilled water (1:1). The layers were 
separated and the organic layer was washed with saturated aqueous NaHCO3 and distilled water 
(1:1) before drying (MgSO4), filtering and concentrating in vacuo. Column chromatography 
isolated the target compound. 
  General Procedure for the Synthesis of Compounds 11 – 12. The appropriate aniline 
(1.0 equiv.) and anhydrous MgSO4 (excess) were suspended in THF (0.5 M) in air at RT and 
charged with the appropriate benzaldehyde in one go. After 16 h, the mixture was filtered in vacuo, 
washing with EtOAc, and concentrated in vacuo, before suspending in TFE or methanol (0.2 M) 
and mixing with sodium borohydride (4.0 equiv.) portion-wise at RT in air. After 16 h, the reaction 
was concentrated to a low volume in vacuo and partitioned using EtOAc with saturated aqueous 
NaHCO3 and distilled water (1:1). The layers were separated and the aqueous layer was extracted 
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with EtOAc. The combined organic layers were dried (MgSO4), filtered and concentrated in vacuo. 
Column chromatography isolated the target compound. 
 General Procedure for the Synthesis of Compounds 14 – 17. The amine salt (1.0 equiv.) 
and the sulfonyl chloride (1.1 equiv.) were dissolved in DCM (0.2 M) under nitrogen and cooled 
to 0 °C, before adding anhydrous diisopropylethylamine (3.0 equiv.) dropwise. The solution was 
stirred at 0 °C for 10 min before being allowed to reach RT. After 16 h, the reaction was quenched 
with 1 M HCl and the layers were partitioned and separated. The aqueous layer was extracted with 
DCM and the combined organic layers were dried (MgSO4), filtered and concentrated in vacuo. 
Column chromatography isolated the target compound. 
 General Procedure for the Synthesis of Compounds 18 – 22. The sulfonamide (1.0 
equiv.) was charged with cesium carbonate (2.0 equiv.) and dissolved in acetonitrile (0.2 M) in air 
before stirring at RT –  50 °C for 20 min. The benzyl or alkyl bromide (1.1 – 1.5 equiv.) was added 
in one go and the reaction was stirred at RT. After 16 h, the reaction was concentrated in vacuo 
and partitioned between EtOAc and distilled water. The layers were separated and the organic 
layer was washed with distilled water. The combined aqueous layer was extracted with EtOAc and 
the combined organic layer was dried (MgSO4), filtered and concentrated in vacuo. Column 
chromatography isolated the target compound. 
 General Procedure for the Synthesis of Compounds 23 – 27. The tert-butyl ester (1.0 
equiv.) was dissolved in DCM or chloroform in air at RT before mixing with trifluoroacetic acid 
(3:1, 2:1 or 1:1) (final concentration, 0.2 M). After 3 h, the reaction was concentrated in vacuo, 
azeotroping with DCM, to isolate the target compound without further purification. 
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 General Procedure for the Synthesis of Compounds 28 – 35. The carboxylic acid (1.2 
equiv.) and dichlorotriphenylphosphorane (2.4 equiv.) were dissolved in chloroform (0.15 – 0.2 
M) under nitrogen and stirred vigorously at RT for 15 min, prior to addition of the aniline (1.0 
equiv.), neat or as a solution in chloroform (0.3 M), and the vial was irradiated at 100 °C for 1 h 
(high absorbance). The solution was concentrated in vacuo and column chromatography isolated 
the target compound.  
 General Procedure for the Synthesis of Compounds 44 – 51, and 59. The benzoic acid 
(1.0 equiv.) was dissolved in THF (0.05 M) under nitrogen and cooled to 0 °C before mixing with 
oxalyl chloride (5.0 equiv.) and DMF (1 – 2 drops). After 2 h, the reaction was concentrated in 
vacuo, re-purged with nitrogen and dissolved in THF (0.05 M). Diisopropylethylamine (4.0 equiv.) 
and O-benzylhydroxylamine (2.0 equiv.) were added and the reaction was stirred at RT. After 16 
h, the reaction was quenched with 1 M HCl and partitioned with EtOAc. The layers were separated 
and the organic layer was washed with 1 M HCl. The combined aqueous layer was extracted with 
EtOAc and the combined organic layer was dried (MgSO4), filtered and concentrated in vacuo. 
Column chromatography isolated the target compound.  
 General Procedure for the Synthesis of Compound 56. Di-tert-butyl dicarbonate (1.0 
equiv.) was added, as a solution in THF (7.0 M), to the amine (2.0 equiv.) in THF (0.5 M) in air at 
RT. After 24 h, the reaction was partitioned between EtOAc and 0.5 M HCl. The layers were 
separated and the organic layer was washed with 0.5 M HCl. The combined aqueous layer was 
extracted with EtOAc and the organic layer was dried (MgSO4), filtered and concentrated in vacuo 
to give the target compound without further purification. 
 General Procedure for the Synthesis of Compound 57. Sodium hydride (60% in mineral 
oil) (3.0 equiv.) was added, in one go, to the carbamate (1.0 equiv.) in DMF (0.40 M) at RT, 
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followed by iodomethane (1.5 equiv.) after 15 min. After 24 h, the reaction was quenched with 
distilled water and extracted with diethyl ether. The organic layer was dried (MgSO4), filtered and 
concentrated in vacuo. Column chromatography isolated the target compound. 
 General Procedure for the Synthesis of Compound 58. The carbamate (1.0 equiv.) was 
dissolved in chloroform in air at RT, and mixed with trifluoroacetic acid (3:1) (final concentration, 
0.2 M). After 22 h, the reaction was concentrated in vacuo and partitioned between EtOAc and 1 
M NaOH. The layers were separated and the aqueous layer was extracted with EtOAc. The organic 
layer was dried (MgSO4), filtered and concentrated in vacuo to give the target compound without 
further purification. 
Cytotoxicity Assays in MDA-MB-231 and MDA-MB-468 Breast Cancer Cells, MV4-
11 and MOLM-13 Acute Myeloid Leukemia (AML) Cells, K562 Chronic Myeloid Leukemia 
(CML) Cells and MRC-9 Human Lung Fibroblasts. MDA-MB-231 and MDA-MB-468 cells 
were grown in Dulbecco’s Modified Eagles Medium (DMEM) supplemented with 10% FBS 
(Sigma-Aldrich). MV4-11, MOLM-13, K562 and MRC-9 cells were maintained in IMDM and 
RPMI-1640 media, respectively, and supplemented with 10% FBS (Sigma-Aldrich). 10,000 cells 
were plated per well in 96-well flat-bottom sterile culture plates with low-evaporation lids (Costar 
#3997). After 24 h, inhibitors and a vehicle control (0.5% DMSO) were added (final concentration 
100 µM) and the cells were incubated for 72 h at 37 °C in 5% CO2. Inhibitors were examined in 
triplicate at a maximal concentration of 50.0 µM, followed by 50% dilutions in subsequent wells 
(25.0, 12.5, 6.25, 3.125, 1.5625, 0.78125, 0.390625, 0.195313 and 0.097656 µM). After 72 h, wells 
were treated with CellTiter-Blue® (Promega #G808A) (20 µL/well) and the plates were incubated 
using standard cell culture conditions for 1 – 4 h. Plates were shaken for 10 s and fluorescence was 
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recorded at 560/590 nm using a Cytation 3 spectrophotometer. IC50 values were determined using 
non-linear regression analysis with GraphPad Prism 6.0 (GraphPad Software Inc.). 
 Cytotoxicity Assays in AR230 and AR230R CML cells. Cells were maintained in RPMI-
1640 culture media with L-glutamine (Gibco #11875) supplemented with 10% FBS. In addition, 
AR230R cells were cultured in the presence of 5.0 µM imatinib. Inhibitors were diluted 1000-fold 
in 100% DMSO into 96-well flat-bottom polystyrene TC-treated culture plates (Falcon #353072). 
AR230 cells were plated at 5,000 cells/well and AR230R cells were plated at 15,000 cells/well in 
culture media (100 µL) and incubated with inhibitors at 37 °C and 5% CO2 for 48 h. Inhibitors 
were tested in duplicate at a maximum concentration of 31.6 µM, followed by half-logarithmic 
dilutions between wells (10.0, 3.16, 1.00, 0.316, 0.100, 0.032, 0.010, 0.0032 and 0.001 µM). A 
vehicle lane (0.1% DMSO) was also included. Following incubation, MTS reagent (CellTiter96, 
Promega) (20 µL) was added to each well, followed by incubation at 37 °C and 5% CO2 for 3 – 4 
h. Absorbance for each well was measured using an Epoch spectrophotometer (Biotek) at 490 nm 
and IC50 values were determined using non-linear regression analysis with GraphPad Prism 6.0 
(GraphPad Software Inc.).  
 Cytotoxicity Assays in Glioblastoma Brain Tumor Stem Cells (GBM BTSCs). Cells 
were cultured from tumor surgical specimens obtained following consent from adult GBM patients 
during operative procedures and approved by the University of Calgary Ethics Review Board. 
BTSC cultures were initiated in serum-free culture media (SFM), containing tissue culture water 
(150 mL), 10X DMEM (Gibco #12100-046) and F12 (Gibco #21700-075) (20 mL), Hormone Mix 
(20 mL), 30% glucose (Sigma-Aldrich #G7528) (4 mL), 7.5% NaHCO3 (Sigma-Aldrich #S5761) 
(3 mL) and 1 M HEPES (Sigma-Aldrich #H4034) (1 mL). Non-adherent spheres were formed 
after 7-21 days in culture. BTSC cultures were passaged until they stabilized (5 – 10 passages) 
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before being cryopreserved in 10% DMSO (Sigma-Aldrich) in SFM until required. All cultures 
were used within 15 passages after thawing. 
BTSC spheres were dissociated to single cells by incubating with Accumax (Innovative 
Technologies) (1 mL per T25 flask of cells, 5 min, 37 °C), seeded at 2,500 cells/well in TC-grade 
low-adherence 96-well culture plates (Nalgene) and treated with either vehicle (DMSO) or 
inhibitor (stock concentration 10 mM in DMSO) one day after plating. Inhibitors were 
administered in logarithmic or half logarithmic serial dilutions, with eight concentrations measured 
between 100 nM and 20 µM, and cell viability was assessed after 48 h using the Alamar blue assay, 
according to manufacturer instructions. Experiments were performed in triplicate with a minimum 
of 3 wells per condition. IC50 values were determined using non-linear regression analysis with 
GraphPad Prism 6.0 (GraphPad Software Inc.). 
 Cytotoxicity Assays in D425 (Primary) and D458 (Recurrent) Medulloblastoma Cells. 
Cells were cultured in DMEM high glucose (Life Technologies #11965-118) supplemented with 
1% penicillin–streptomycin, and 20% FBS. To evaluate the IC50 concentration of each inhibitor, 
1000 cells were plated into each well of a tissue culture-treated 96-well flat-bottom plate 
(Falconâ) with 150 µL of DMEM high glucose with 1% FBS and 50 µL of serially diluted 
inhibitor. The inhibitor was plated at a concentration of 20 µM, following two-fold dilutions, 
resulting in a final tested concentration of 39 nM. The cells were allowed to proliferate for 3 days 
at 37 °C in the presence of the inhibitor or DMSO before 20 µL of Presto Blue (Life Technologies), 
a fluorescent cell metabolism indicator, was added to each well approximately 4 h prior to the 
readout time point. Fluorescence was measured using a FLUOstar Omega Fluorescence 556 
Microplate reader (BMG LABTECH) at excitation and emission wavelengths of 540 – 570 nm, 
respectively. Readings were analyzed by Omega software by plotting percent cell viability versus 
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log dilutions of the inhibitors to determine the IC50 value. 
 Cytotoxicity Assays in Pancreatic Cancer Pa03C, Pa02C, 10.05 and KPC Cells. 
Patient-derived tumor cells and CAF19 cells were a kind gift from Dr. Anirban Maitra (The Johns 
Hopkins University) and KPC cells (TB32908 male) were a kind gift from Drs. David Tuveson 
and Christopher Frese.  All cell lines were authenticated via STR analysis (IDEXX BioResearch) 
and checked routinely for mycoplasma contamination. The proliferative capacity of Pa03C, 10.05, 
Pa02C, and KPC cells in monolayer was assessed using Alamar blue. For Alamar blue assays, 
PDAC cells were plated at 2000 cells/well in 96-well plates and treated with AES-135 for 72 h. 
Assays were performed in at least triplicate. 
 Glutathione Stability Assay using HPLC. Assays were run using a Hewlett Packard 
Series 1100 analytical HPLC system fitted with an Agilent ZORBAX 3.5 µm Eclipse XDB-C18 
4.6 mm x 75 mm column at room temperature. Eluent flow was set to 1.200 mL/min, using gradient 
mixtures of (A) MilliQ water with 0.1% (v/v) TFA and (B) HPLC-grade acetonitrile. Glutathione 
conjugation was measured by performing a linear elution gradient: A:B (1:0 à 0:1, 8.0 min à 2.0 
min), with UV detection set to 254 nm. Changes in the absorbance profile of the inhibitor were 
measured across time, with reductions in HPLC peak area corresponding to a decay in the 
concentration of the parent compound. 
 Glutathione Stability Assay using 19F NMR. 1D 19F NMR experiments were recorded at 
37 oC on a 600 MHz spectrometer with an H(F)CN room temperature probe (number of transients, 
800) (scan width, 150 ppm). Compounds were prepared at a final concentration of 100 µM in a 
solution comprising 100 mM HEPES, pH 7.4, 100 µM 5-fluorotryptophan, 1 mM reduced L-
glutathione (in blank samples, an equivalent volume of HEPES solution was added), 40% DMSO 
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and 10% D2O. All samples were incubated at 37 oC for 16 h, and the data was processed and 
analyzed using MestreNova 10.0. 
 Western Blotting in MDA-MB-231 Breast Cancer Cells and MV4-11 AML Cells. All 
cells were lysed with radioimmunoprecipitation assay (RIPA) buffer: 20 mM Tris, pH 7.4, 150 
mM NaCl, 0.5% deoxycholate, 1% Triton X-100, and 0.1% sodium dodecyl sulfate (SDS). Total 
protein was measured using BCA assay (Sigma-Aldrich). In each assay, clarified protein was 
resolved on a 4 – 15% polyacrylamide–SDS gel and transferred to a PVDF membrane (Bio-Rad). 
The membranes were blocked with a 5% solution of skimmed milk powder in TBST and incubated 
for ≥ 1 h followed by an overnight incubation at 4 °C in primary antibody 1:1000 dilution.  Blots 
were probed with antibodies against pSTAT5, total STAT5, c-myc, Bcl2, and cleaved PARP. Beta 
actin (Santa Cruz Biotechnology, #SC-835) was used as a loading control. The PVDF membrane 
was washed with TBST (3 times, 5 min each).  
A horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG secondary antibody (Cell 
signaling, #7076S), a fluorescently labelled secondary antibody Anti-mouse IgG (H+L), 
F(ab')2 Fragment (Alexa Fluor® 488 Conjugate, #4408), or an Anti-rabbit IgG (H+L), 
F(ab')2 Fragment (Alexa Fluor® 647 Conjugate, #4414) was applied to the membrane, at a 1:5000 
dilution, and incubated for 1 h at room temperature. The blots were then rinsed again 3 times in 
TBST for 10 min each.  Bands were visualized using clarity western ECL substrate 
luminal/enhancer solution and peroxide solution (1:1) for HRP secondary antibody, according to 
manufacturer instructions (BioRAD) and analyzed using Image Lab software (Bio-Rad).  
 Western Blotting in Glioblastoma Brain Tumor Stem Cells (GBM BTSCs). For protein 
analysis following drug treatment, BTSCs were dissociated to single cells and treated with drug or 
vehicle (DMSO) for 24 h. Cell pellets were lysed in RIPA buffer (50 mM Tris, 150 mM NaCl, 
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0.1% SDS, 0.5% Na deoxycholate, and 1% NP40) and Complete Protease Inhibitor Cocktail 
Tablets (Roche); 20 µg of protein lysate was separated by SDS-PAGE and transferred onto a 
nitrocellulose membrane according to standard protocols. Membranes were blocked in Tris-
buffered saline with 5% non-fat dry milk and incubated overnight with primary antibody at 4 °C 
followed by a 1 h incubation with the appropriate horseradish peroxidase–conjugated secondary 
antibody. Images were acquired on an Amersham imager 600 using Amersham ECL Select 
Western Blotting Detection Reagent. Primary antibodies: pSTAT3 (Anti-phosphotyrosine 705 
STAT3 antibody, Cell signaling #9145S); STAT3 (1:1000, Santa Cruz Biotechnology, SC-8019); 
Actin (1:2000; Santa Cruz Biotechnology, SC-1615). Secondary antibodies: donkey anti-mouse 
(1:5000, Millipore); donkey anti-rabbit (1:5000, Millipore); donkey anti-goat (1:5000, Millipore). 
 Determination of Half-Life and Intrinsic Clearance in Mouse Hepatocytes. 
Bioanalytical evaluation of in vitro half-lives and rates of intrinsic clearance in mouse hepatocytes 
was performed at Pharmaron using a liquid chromatography system (Shimadzu) and an API 5500 
mass spectrometer (AB Inc. Canada) with electrospray ionization (ESI) interface. The LC system 
was equipped with a Phenomenex Synergi 4 µm Hydro-PR 80A (2.0 x 30 mm) column, through 
which 5 µL injections were made, eluting at 0.65 mL/min at 25 °C, with a mobile phase consisting 
of: A) MilliQ water with 0.1% (v/v) formic acid; B) acetonitrile with 0.1% (v/v) formic acid. 
Gradients were run over 2.0 min as follows: (A:B, 95:5, 0.0 – 0.3 min à 0:100, 0.3 – 0.8 min à 
95:5, 1.2 – 1.5 min à 2.0 min). The MS was equipped with a turbo spray ion source, detecting 
samples with an ionspray voltage of +5500 V (positive MRM) and -4500 V (negative MRM), and 
using the additional instrument parameters: temperature 500 °C, collision gas 6.0 L/min, curtain 
gas 30 L/min, nebulize gas 50 L/min, and auxiliary gas 50 L/min. Hepatocytes were sourced from 
male ICR/CD-1 mice (BioreclamationIVT #M00505, Lot no. XNN) and cryopreserved until used. 
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Calculations were carried out using Excel (Microsoft) and peak areas were determined using the 
extracted ion chromatograms. The in vitro half-lives of each compound were calculated using 
regression analysis of the %parent disappearance vs. time curve and the following equation: t1/2 = 
0.693/k, where t1/2 is the half-life (min) and k is the rate constant (min-1). Conversion of the half-
life to the in vitro intrinsic clearance (CLint, µL/min/106 cells) was done using the following 
equation: CLint = kV/N, where V is the incubation volume (200 µL) and N is the number of 
hepatocytes per well (0.5 x 106).  
 Mouse Plasma Protein Binding Assay. Determination of protein binding in mouse 
plasma was performed at Pharmaron using a liquid chromatography system (Shimadzu) and an 
API 4000 mass spectrometer (AB Inc. Canada) with electrospray ionization (ESI) interface. The 
LC system was equipped with a Phenomenex Synergi 4.0 µm Hydro-RP 80A (2.0 x 30 mm) new 
column, through which 10 µL injections were made, eluting at 0.65 mL/min at room temperature. 
The mobile phase consisted of: A) MilliQ water with 0.1% (v/v) formic acid; B) acetonitrile with 
0.1% (v/v) formic acid. Gradients were run over 1.4 min and proceeded as follows: (A:B, 95:5 à 
0:100, 0.0 – 0.8 min, 0:100, 0.8 – 1.1 min, 0:100 à 95:5, 1.1 – 1.2 min, 95:5, 1.2 – 1.4 min). The 
MS was equipped with a turbo spray ion source, detecting samples with an ionspray voltage of -
4500 V (negative MRM), and using the additional instrument parameters: temperature 500 °C, 
collision gas 6.0 L/min, curtain gas 30 L/min, nebulize gas 50 L/min, and auxiliary gas 50 L/min. 
Plasma from male and female CD-1 mice (BioreclamationIVT) was stored at -80 °C until required. 
Ketoconazole was used as a control. Experiments were run in duplicate and calculations were 
carried out using Microsoft Excel. Concentrations of the test compound in the buffer and plasma 
chambers were determined from peak area ratios. 
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 Determination of Experimental LogD7.4. Determination of experimental LogD7.4 was 
performed at Pharmaron using a liquid chromatography system (Shimadzu) and an API 4000 mass 
spectrometer (AB Inc. Canada) with electrospray ionization (ESI) interface. The LC system was 
equipped with a Phenomenex Synergi 4.0 µm Hydro-RP 80A (2.0 x 30 mm) new column coupled 
with preguard, through which 10 µL injections were made, eluting at 0.65 mL/min at room 
temperature. The mobile phase consisted of: A) MilliQ water with 0.1% (v/v) formic acid; B) 
acetonitrile with 0.1% (v/v) formic acid. Gradients were run over 1.4 min and proceeded as 
follows: (A:B, 95:5 à 0:100, 0.0 – 0.8 min, 0:100, 0.8 – 1.1 min, 0:100 à 95:5, 1.1 – 1.2 min, 
95:5, 1.2 – 1.4 min). The MS was equipped with a turbo spray ion source, detecting samples with 
an ionspray voltage of +5500 V (positive MRM), and using the additional instrument parameters: 
temperature 500 °C, collision gas 10 L/min, curtain gas 30 L/min, nebulize gas 55 L/min, and 
auxiliary gas 55 L/min. Progesterone was used as a control and experiments were performed in 
duplicate. 
 Permeability Determination using a Lipid-PAMPA. Determination of compound cell 
permeability using a parallel artificial membrane permeability assay (PAMPA) was performed at 
Pharmaron using a liquid chromatography system (Shimadzu) and an API 4000 mass spectrometer 
(AB Inc. Canada) with electrospray ionization (ESI) interface. The LC system was equipped with 
a Phenomenex Synergi 4 µm Hydro-PR 80A (2.0 x 30 mm) column, through which 10 µL 
injections were made, eluting at 0.65 mL/min at 25 °C, with a mobile phase consisting of: A) 
MilliQ water with 0.1% (v/v) formic acid; B) acetonitrile with 0.1% (v/v) formic acid. Two 
gradients were run over 1.4 (Run 1) and 2.0 min (Run 2). Run 1 proceeded as follows: (A:B, 95:5 
à 0:100, 0.0 – 0.3 min, 0:100 à 95:5, 0.8 – 1.1 min, 95:5, 1.1 – 1.4 min). Run 2 proceeded as 
follows: (A:B, 95:5, 0.0 – 0.3 min, 95:5 à 0:100, 0.3 – 0.8 min, 0:100 à 95:5, 1.2 – 1.5 min, 
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95:5, 1.5 – 2.0 min). The MS was equipped with a turbo spray ion source, detecting samples with 
an ionspray voltage of +5500 V (positive MRM) and -4500 V (negative MRM), and using the 
additional instrument parameters: temperature 500 °C, collision gas 6.0 L/min, curtain gas 30 
L/min, nebulize gas 50 L/min, and auxiliary gas 50 L/min. Experiments were conducted in 
triplicate and methotrexate and testosterone were used as positive controls. 
 Permeability Determination using a Caco-2 Assay. Determination of compound cell 
permeability using a Caco-2 cell line was performed at Pharmaron using a liquid chromatography 
system (Shimadzu) and an API 5500 and API 4000 mass spectrometer (AB Inc. Canada) with 
electrospray ionization (ESI) interface. The LC systems were equipped with a Phenomenex 
Kinetex 1.7 µm C8 100A (2.1 x 30 mm) column, and a Phenomenex Kinetex 1.7 µm C18 100A 
(2.1 x 30 mm) column, through which 10 and 3.0 µL injections were made, eluting at 0.65 mL/min 
at 40 and 25 °C. The mobile phase consisted of: A) MilliQ water with 0.1% (v/v) formic acid; B) 
acetonitrile with 0.1% (v/v) formic acid. Two gradients were run over 2.0 (Run 1) and 1.4 min 
(Run 2). Run 1 (10 µL injection) proceeded as follows: (A:B, 95:5, 0.0 – 0.3 min, 95:5 à 0:100, 
0.3 – 0.8 min, 0:100 à 95:5, 1.2 – 1.5 min, 95:5, 1.5 – 2.0 min). Run 2 (3.0 µL injection) proceeded 
as follows: (A:B, 95:5 à 0:100, 0.0 – 0.8 min, 0:100 à 95:5, 1.1 – 1.2 min, 95:5, 1.2 – 1.4 min).  
The MS was equipped with a turbo spray ion source, detecting samples with an ionspray voltage 
of +5500 V (positive MRM) and -4500 V (negative MRM), and using the additional instrument 
parameters: temperature 500 °C, collision gas 6.0 L/min, curtain gas 30 L/min, nebulize gas 50 
L/min, and auxiliary gas 50 L/min. Transepithelial electrical resistance (TEER) was measured 
across the monolayer, using a Millicell Epithelial Volt-Ohm measuring system (Millipore), and 
the plate was returned to the incubator. TEER values were calculated using the following equation: 
TEER (ohm cm2) = TEER measurement (ohm) x membrane area (cm2). Studies were run in 
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duplicate and Digoxin, Prazosin and Propranolol were used as control compounds. Internal 
standards consisted of 100 nM alprazolam with 200 nM labetalol (positive mode), and 2.0 µM 
ketoprofen with 200 nM labetalol (negative mode). Lucifer Yellow fluorescence to monitor 
monolayer integrity was measured in a fluorescence plate reader at 485 nm excitation and 530 nm 
emission.  
 Inhibition of Histone Deacetylases (HDACs). Biochemical HDAC assays were 
performed at Nanosyn using microfluidic detection technology (electrophoretic mobility shift 
assay).  Full-length recombinant human HDACs 3, 6, 8 and 11 were produced in SF9 baculoviral 
system. Reactions were assembled in 384-well plates (total volume 20 µL) and the test compounds 
were serially pre-diluted in DMSO and added by acoustic dispenser (Labcyte550®) directly to the 
reaction buffer comprising: 100 mM HEPES (pH 7.5), 25 mM KCl, 0.1% bovine serum albumin, 
0.01% Triton X-100 and enzyme. Final concentrations of HDACs 3, 6, 8 and 11 were 0.5, 60, 5.0 
and 10 nM, respectively. Concentration of DMSO was equalized at 1% in all samples. Reactions 
were initiated by addition of the fluorescently FAM-labelled acetylated peptide substrate to a final 
concentration of 1 µM with HDACs 3, 6 and 8, and 100 µM with HDAC11. Change in the relative 
fluorescence intensity of the substrate and product peaks is the parameter measured, reflecting the 
enzyme activity. Activity in each test sample was determined as the product sum ratio (PSR): 
P/(S+P), where P is the peak height of the product and S is the peak height of the substrate.  For 
each compound, enzyme activity was measured at 12 concentrations spaced by 3x dilution 
intervals, ranging from 30.0 to 0.0001694 µM. Reference compound JNJ-26481585 (Quisinostat) 
was tested in an identical manner. Negative control samples (0% inhibition in the absence of 
inhibitor, DMSO only) and positive control samples (100% inhibition, in the absence of enzyme) 
were assembled in replicates of four and were used to calculate % inhibition values in the presence 
Page 42 of 57
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
43 
 
of compounds. Percent inhibition (Pinh) was determined using the following equation: Pinh = 
(PSR0% - PSRinh)/(PSR0% - PSR100%)*100, where PSRinh is the product sum ratio in the presence 
of inhibitor, PSR0% is the product sum ratio in the absence of inhibitor and PSR100% is the product 
sum ratio in 100% inhibition control samples. To determine IC50 values, the inhibition curves (Pinh 
versus inhibitor concentration) were fitted by 4 parameter sigmoid dose-response model using 
XLfit software (IDBS). 
 Molecular Modeling. Receptor and ligand preparation protocols utilized molecular 
visualization software PyMOL v.1.7.4.5, advanced cross-platform molecular editing software 
Avagadro v.1.2.0 as well as graphical user interface software AutoDockTools (ADT) v.4.2.6. The 
docking simulations were performed by AutoDock Vina v.1.1.2. Analysis of the docking results 
were also visualized by PyMOL v.1.7.4.5. Three-dimensional crystal structures of the human 
HDAC isoforms were retrieved from the RCSB protein data bank (www.rcsb.org): hHDAC3 (PDB 
4A69), hHDAC6 (PDB 5EDU), hHDAC8 (PDB 1T64). ADT was used to remove water 
molecules, assign polar hydrogens, unite atom Kollman charges and assign Gasteiger charges and 
solvation parameters. ADT does not naturally recognize charged inorganic heteroatoms, hence, 
the charges on Zinc in all three enzymes was manually modelled to +2. These studies utilized three 
distinct ligands; AES-135, 6 and SAHA (Vorinostat). Energy minimization calcuations utilizing 
molecular mechanics and the steepest descent algorithm were used to produce low energy 
conformers of each ligand. The grid size was set to 40 x 40 x 40 xyz points, with a grid spacing of 
0.497 Å. Binding poses with the most favourable free energy of binding values were visualized 
using PyMOL. 
 Pharmacokinetic (PK) Studies. All animal studies were conducted under the guidelines 
of the National Institute of Health and were approved by the Institutional Animal Care and Use 
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Committee of Indiana University School of Medicine. Animals were maintained under pathogen-
free conditions and a 12 h light-dark cycle. NOD SCID gamma (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) 
or NSG mice were administered 20 mg/Kg AES-135 IP in CremophorEL:EtOH (1:1, 4% final 
volume) / sterile saline and blood was collected via tail vein at multiple timepoints between 0.5 – 
24 h following administration. AES-135 was quantified in plasma using an internal standard 
(sorafenib), liquid-liquid extraction with ethyl acetate and HPLC-MS/MS (Agilent HPLC, Applied 
Biosystems API 4000).  The HPLC was run in isocratic mode using acetonitrile:5 mM ammonium 
acetate (20:80, v/v).  The API 4000 was run in negative mode for AES-135 (Q1/Q3:  692/192) and 
positive mode for sorafenib (Q1/Q3, 465/270).  The lower limit of quantification was 1 ng/mL 
using 20 µL of blood or plasma.   
Pharmacokinetic parameters for AES-135 including area under the curve (AUC), area under the 
moment curve (AUMC), and t½, were estimated using noncompartmental methods with Excel®.  
The maximum plasma concentration (Cmax) and time of Cmax (tmax) were obtained from the data.  
The AUC from zero to infinity (AUC0-¥) was estimated from the AUC0-t (time zero to the last 
quantifiable concentration Clast) and the AUC from Clast to infinity, Clast/kel, where kel is the rate 
constant of elimination.  The AUMC0-¥ was estimated by an analogous manner.  The systemic 
clearance (Cl/F, where F = bioavailability) of AES-135 was calculated from the dose and AUC0-
¥. The apparent volume of distribution (Vdss) was estimated by the following equation:  
(dosage/AUC0-¥) x (AUMC0-¥/AUC0-¥). 
 Tumor and Cancer-Associated Fibroblast (CAF) 3D Co-Cultures. Patient-derived 
tumor cells and CAF19 cells were a kind gift from Dr. Anirban Maitra (The Johns Hopkins 
University) and KPC cells (TB32908 male) were a kind gift from Drs. David Tuveson and 
Christopher Frese. TdTomato-labeled PDAC cells and EGFP-labeled CAFs were resuspended in 
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DMEM media containing 3% Reduced Growth Factor Matrigel (BD Biosciences) and 5% FBS at 
a cell ratio of 1:4 (tumor:CAF) and fed or treated with AES-135 on days 4 and 8 following plating. 
Both cell populations were quantitated for intensity and area via Thermo ArrayScan at day 12 of 
co-culture.    
 Orthotopic Tumor Treatment. All animal studies were conducted under the guidelines 
of the National Institute of Health and were approved by the Institutional Animal Care and Use 
Committee of Indiana University School of Medicine. Animals were maintained under pathogen-
free conditions and a 12 h light-dark cycle. C57Bl/6 mice (Jackson Laboratory) were 
orthotopically implanted with 5 x 104 KPC cells. The mice were randomized into 2 groups of 10 
mice each just before commencing treatment (7 days post implantation). The treatment regime 
consisted of 50 mg/kg AES-135 IP prepared in CremophorEL:EtOH (1:1, 8% final volume) in 
sterile PBS. The vehicle mice received CremophorEL:EtOH (1:1, 8% final volume) in sterile PBS. 
Both groups were treated 5 days a week for 1 month. Mice were euthanized when they exhibited 
signs of deterioration such as lack of grooming and appetite, loss of weight and activity etc. Data 
was analyzed using Kaplan-Meier curves (Graphpad Prism 6), and statistical significance was 
determined using the Logrank test and P values <0.05 were considered statistically significant. 
 
Ancillary Information: 
Supporting Information 
The supporting information is available free of charge on the ACS Publications website at 
http://pubs.acs.org. 
o Molecular formula strings for final compounds (CSV) 
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o Chemicals and solvents, analytical techniques and chromatography methods; cytotoxicity 
results of top compounds in breast, AML, CML, MDB and pancreatic cancer cell lines, GBM 
BTSCs, and non-cancerous human lung fibroblasts; glutathione stability data by HPLC and 19F 
NMR; Western blots in breast cancer cells, AML cells and GBM BTSCs; in vitro half-life and 
intrinsic clearance rates of top compounds in mouse hepatocytes; mouse plasma protein binding 
assay data; determination of experimental LogD7.4; PAMPA and Caco-2 permeability data; in 
vivo PK data and orthotopic tumor treatment data; HDAC inhibition assay data; in silico 
modelling/docking data; chemical synthesis procedures for all compounds with NMR, LRMS, 
HRMS and HPLC data; 1H NMR spectra for all final compounds (PDF) 
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piperazineethanesulfonic acid); CAF, cancer-associated fibroblast; TGF-β, transforming growth 
factor beta; KPC, KrasLSL.G12D/+, p53R172H/+, PdxCretg/+; PDAC, pancreatic ductal 
adenocarcinoma; PanINs, Pancreatic Intraepithelial Neoplasia; LRMS, low-resolution mass 
spectrometry; HRMS, high-resolution mass spectrometry 
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